国浩律师（上海）事务所 关 于 浙江医药股份有限公司 差异化分红事项 之 法 律 意 见 书 中国上海市静安区山西北路 99 号苏河湾中心 25-28 楼 邮编：200085 25-28/F, Suhe Centre, 99 North Shanxi Road, Jing'an District, Shanghai, China 电话/Tel: +86 21 52341668 传真/Fax: +86 21 52433320 网址/Website:http://www.grandall.com.cn 1 国浩律师(上海)事务所 法律意见书 国浩律师(上海)事务所 法律意见书 目 录 | 第一节 律师声明事项 . | | --- | | 第二节 正 文 ……………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………… 4 | | 一、本次差异化分红的原因…………………………………………………………………………………………………………………………………………………………… ...

[Core Performance Forecast Data](index=1&type=section&id=I.%E3%80%81Current%20Period%20Performance%20Forecast) The company forecasts H1 2025 net profit attributable to shareholders to be **RMB 600-720 million**, a **90.28%-128.33% increase**, with non-recurring adjusted net profit at **RMB 590-708 million**, up **86.27%-123.53%** H1 2025 Performance Forecast | Metric | Estimated Amount (RMB Million) | YoY Growth | | :--- | :--- | :--- | | **Net Profit Attributable to Shareholders** | 600.00 - 720.00 | 90.28% - 128.33% | | **Net Profit After Non-Recurring Items** | 590.00 - 708.00 | 86.27% - 123.53% | [Prior Period Performance Review](index=1&type=section&id=II.%E3%80%81Prior%20Period%20Operating%20Performance%20and%20Financial%20Position) In H1 2024, the company reported **RMB 315.33 million** in net profit attributable to shareholders, **RMB 316.74 million** in non-recurring adjusted net profit, and **RMB 0.33** in basic earnings per share, serving as the basis for this forecast H1 2024 (Prior Period) Performance | Metric | Amount (RMB) | | :--- | :--- | | Total Profit | 334.59 million | | Net Profit Attributable to Parent Company Shareholders | 315.33 million | | Net Profit After Non-Recurring Items | 316.74 million | | Earnings Per Share | 0.33 | [Analysis of Performance Increase Drivers](index=2&type=section&id=III.%E3%80%81Primary%20Reasons%20for%20Current%20Period%20Performance%20Increase) The significant performance increase is primarily driven by the company's life nutrition products segment, which saw robust market demand and rising sales prices for its main products, boosting overall revenue and profit - The primary driver for performance growth is the life nutrition products segment, with increased market demand and sales prices for its leading products compared to the prior year, leading to higher sales revenue[6](index=6&type=chunk) [Risk Warning and Other Disclosures](index=2&type=section&id=IV.%E3%80%81Risk%20Warning) The company states that this performance forecast is based on unaudited preliminary calculations, with final accurate financial data subject to the official H1 2025 report, and confirms no material uncertainties affecting the forecast's accuracy - This performance forecast data is unaudited and preliminary, investors should refer to the company's officially disclosed H1 2025 semi-annual report for final figures[7](index=7&type=chunk)[8](index=8&type=chunk) - The company declares no material uncertainties exist that would affect the accuracy of this performance forecast[7](index=7&type=chunk)

Investment Rating - The report maintains an "Outperform" rating for the basic chemical industry [2] Core Viewpoints - The basic chemical sector has shown better performance than the market, with a year-to-date increase of 8.9%, outperforming the Shanghai Composite Index by 4.2 percentage points [4][16] - The global potash market is characterized by oligopoly, with major producers controlling supply and prices. Recent production cuts by key players are expected to sustain potash market conditions [5][27] - Phosphate supply remains tight, with stable prices and potential improvements in export opportunities as demand increases [5][27] Summary by Sections 1. Core Viewpoints - Policies are expected to improve supply-demand dynamics in the chemical sector, with a focus on cyclical investment opportunities [13] - The chemical industry is entering a new long-term prosperity cycle, driven by improved fundamentals and reduced risks [13][14] 2. Overall Performance of the Chemical Sector - The basic chemical industry index increased by 1.5% during the week, outperforming the Shanghai Composite Index by 0.4 percentage points [16] - Year-to-date, the basic chemical industry index has increased by 8.9%, significantly outperforming both the Shanghai Composite and ChiNext indices [16][18] 3. Individual Stock Performance in the Chemical Sector - Among 424 stocks in the basic chemical sector, 298 stocks rose while 123 fell during the week [25] - The top performers included companies like Shangwei New Materials (+72.9%) and Hongbo New Materials (+24.7%) [25][26] 4. Key News and Company Announcements - The autumn fertilizer preparation has begun, with a focus on investment opportunities in potash and phosphate fertilizers [27] - Major potash producers have announced production cuts, which are expected to tighten supply and support prices [5][27] - Phosphate prices remain stable, with potential for improved export conditions as demand increases [5][27] 5. Product Price Changes - The report highlights significant price increases in various chemical products, with notable gains in dimethylamine (+16.7%) and fatty alcohol (+8.2%) [6] - Conversely, urea prices have seen a significant decline (-15%) [6]

持股 5%以上股东减持计划届满暨未减持股份的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 大股东持股的基本情况 证券代码：600216 证券简称：浙江医药 公告编号：2025-028 浙江医药股份有限公司 本次减持计划实施前，浙江医药股份有限公司（以下简称"公司"）股东国 投高科技投资有限公司（以下简称"国投高科"）持有公司无限售流通股份 150,127,573 股，占公司总股本的 15.61%。 减持计划的实施结果情况 公司于 2025 年 3 月 21 日披露了《浙江医药股份有限公司持股 5%以上股东 集中竞价减持股份计划公告》（公告编号：2025-005），国投高科拟通过集中竞价 交易方式合计减持数量不超过 9,616,377 股，即不超过公司总股本的 1%。 2025 年 7 月 9 日，公司收到国投高科出具的《关于股份减持计划期限届满 的告知函》，截至 2025 年 7 月 9 日，国投高科未对公司股票进行减持，现减持计 划时间已经届满。 | 股东名称 | 国投高科技投资有限公司 | ...

Group 1 - The Artemisinin concept index increased by 0.65%, ranking 10th among concept sectors, with four stocks rising, including Haizheng Pharmaceutical which hit the daily limit, and Zhejiang Medicine, Huaren Shuanghe, and Baiyunshan also showing gains of 0.79%, 0.69%, and 0.08% respectively [1] - The leading decliners in the sector included Rundu Co., New Harmony, and Kunming Pharmaceutical, which fell by 1.41%, 1.36%, and 1.17% respectively [1] - The net inflow of main funds into the Artemisinin concept sector was 95 million yuan, with Haizheng Pharmaceutical receiving the highest net inflow of 105 million yuan, followed by Zhejiang Medicine, New Harmony, and Baihua Pharmaceutical with net inflows of 25.71 million yuan, 9.91 million yuan, and 2.14 million yuan respectively [2][3] Group 2 - In terms of fund inflow ratios, Haizheng Pharmaceutical, Zhejiang Medicine, and Baihua Pharmaceutical had the highest net inflow rates of 9.03%, 5.48%, and 2.27% respectively [3] - The trading performance of key stocks in the Artemisinin concept included Haizheng Pharmaceutical with a daily increase of 10.02% and a turnover rate of 9.22%, while Zhejiang Medicine rose by 0.79% with a turnover rate of 3.19% [3][4] - Other stocks such as New Harmony and Baihua Pharmaceutical experienced declines of 1.36% and 0.41% respectively, with turnover rates of 1.04% and 3.34% [3][4]

Core Viewpoint - The production of feed-grade vitamin E in China has shown a fluctuating upward trend, with a notable decline in 2022 due to losses in the terminal breeding industry, but a gradual recovery is expected in subsequent years [1][12]. Group 1: Industry Overview - Feed-grade vitamin E is a fat-soluble vitamin essential for animal feed, known for its antioxidant properties, which enhance meat quality, growth, and survival rates [3][12]. - The production of feed-grade vitamin E primarily relies on synthetic methods due to higher efficiency and lower costs [3][12]. Group 2: Production Trends - In 2022, China's production of feed-grade vitamin E decreased by 8.3% year-on-year, primarily due to strong cost control measures in the breeding industry [1][12]. - By 2024, the production is projected to reach 63,000 tons, reflecting a year-on-year decline of 3.2% [1][12]. Group 3: Policy Support - Various policies have been introduced to promote the development of feed-grade vitamin E, including its inclusion in the encouraged foreign investment industry directory [5][7]. - The 2025 regulatory framework includes vitamin premix feed in the supervision and inspection projects, indicating a focus on quality and safety [5][7]. Group 4: Competitive Landscape - The market features a mix of international brands like DSM and domestic companies such as Zhejiang Medicine and Xinhecheng, with the latter gaining market share through innovation [14][15]. - Emerging brands are also making their mark through differentiated competition and targeted marketing strategies [14]. Group 5: Future Trends - The demand for feed-grade vitamin E is expected to rise with the ongoing development of the global livestock industry and increased awareness of animal health [19]. - Technological innovations and sustainable production methods will drive the industry's future growth, with a focus on environmental considerations [19].

证券代码：600216 证券简称：浙江医药 公告编号：2025-027 浙江医药股份有限公司 关于回购股份比例达到总股本 1%暨回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司将严格按照《上市公司股份回购规则》 □用于转换公司可转债 □为维护公司价值及股东权益 累计已回购股数 9,619,400股 累计已回购股数占总股本比例 1.00% 累计已回购金额 136,538,850元 实际回购价格区间 13.31元/股~15.10元/股 一、 回购股份的基本情况 浙江医药股份有限公司（以下简称"公司"）于 2025 年 4 月 14 日召开第十 届四次董事会会议，审议通过了《关于以集中竞价交易方式回购股份方案的议案》， 同意公司使用自有资金或自筹资金以集中竞价交易方式回购公司股份，用于后续 实施员工持股计划或股权激励，回购价格不超过人民币 20.83 元/股（含），回购 资金总额不低于人民币 1 亿元（含）且不超过人民币 2 亿元（含），回购期限自董 事会审议通过回购股份方案之日起不超过 12 个月 ...

浙江医药股份有限公司 关于回购股份比例达到总股本 1%暨回购进展公告 证券代码：600216 证券简称：浙江医药 公告编号：2025-027 二、回购股份的进展情况 根据《上市公司股份回购规则》及《上海证券交易所上市公司自律监管指引 第 7 号——回购股份》的相关规定，上市公司回购股份占上市公司总股本的比例 每增加百分之一的，应当自该事实发生之日起三个交易日内予以公告；在回购股 份期间，上市公司应当在每个月的前三个交易日内披露截至上月末的回购进展情 况。现将公司回购股份进展情况公告如下： 截至 2025 年 6 月 30 日，公司通过集中竞价交易方式累计回购股份 9,619,400 股，已回购股份占公司总股本的比例为 1.00%，成交的最高价为 15.10 元/股，最 低价为 13.31 元/股，已支付的总金额为 136,538,850 元（不含交易费用）。本次 回购符合相关法律法规的规定及公司既定的回购股份方案。 三、其他事项 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 202 ...

证券代码：600216 证券简称：浙江医药 公告编号：2025-026 浙江医药股份有限公司 特此公告。 浙江医药股份有限公司董事会 2025 年 6 月 26 日 附件：第十届董事会职工董事简历 马吉琪，女，1991 年生，硕士研究生学历，澳大利亚南昆士兰大学经济学 学士学位，英国南安普顿大学文学硕士学位，经济师。2018 年 7 月至 2021 年 5 月，在浙江创新生物有限公司商务拓展部工作。2021 年 5 月至 2022 年 5 月任公 司信息技术部副部长。2022 年 5 月至今任公司信息技术部部长。2025 年 5 月， 经公司第一次妇女代表大会选举，兼任公司妇联主席。 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 2025 年 6 月 25 日，浙江医药股份有限公司（简称"公司"）召开 2024 年 年度股东大会，审议通过了《关于取消监事会并修订<公司章程>的议案》。根据 《公司章程》规定，公司设职工董事一名，由公司职工通过职工代表大会、职工 大会或者其他形式民主选举产生。 根据《公司法》和《公司章程》 ...

证券代码：600216 证券简称：浙江医药 公告编号：2025-025 浙江医药股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 | 1、出席会议的股东和代理人人数 | 526 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 432,810,314 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 45.2889 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由董事会召集，采取现场和网络投票相结合的方式召开，现场 会议由董事长李男行先生主持。现场会议采取记名投票表决的方式。本次会议的 召集、召开及表决程序符合《公司法》和《公司章程》的规定。 (五) 公司董事、监事和董事会秘书的出席情况 1、公司在任董事11人，出席8人，董事王红卫先生、苍宏宇先生、梁碧蓉女士因 工作原因未能出席会议； 1 (一) 股东大会召开的 ...